Last updated: August 25, 2026
Avelox in Sodium Chloride 0.8% plastic container is the intravenous formulation of moxifloxacin hydrochloride, generally supplied as 400 mg in 250 mL, equivalent to a concentration of 1.6 mg/mL. Bayer developed and commercialized Avelox, while generic manufacturers now supply the same active ingredient and dosage form in the U.S. market.
The product’s financial trajectory has moved through three phases: branded growth after launch, patent-led erosion after loss of exclusivity, and mature generic commoditization. The branded product no longer has a credible basis for premium pricing in the United States. Current value resides in generic hospital supply, contract manufacturing, purchasing agreements, and reliable sterile-injectable production rather than in the Avelox brand.
What is Avelox in Sodium Chloride 0.8% plastic container?
Avelox injection is an intravenous formulation of moxifloxacin hydrochloride, a fluoroquinolone antibacterial. The product is administered as a 400 mg dose, commonly infused over approximately 60 minutes. The commercial presentation is a ready-to-use solution in a plastic container containing 250 mL of 0.8% sodium chloride solution [1].
| Product attribute |
Description |
| Brand |
Avelox |
| Active ingredient |
Moxifloxacin hydrochloride |
| Dosage form |
Intravenous solution |
| Common strength |
400 mg/250 mL |
| Concentration |
1.6 mg/mL |
| Container |
Flexible plastic infusion container |
| Therapeutic class |
Fluoroquinolone antibacterial |
| Original innovator |
Bayer |
| Primary U.S. use |
Hospital and institutional treatment of susceptible bacterial infections |
| Regulatory category |
Small-molecule prescription drug |
| Biosimilar pathway |
Not applicable |
The label includes indications such as community-acquired bacterial pneumonia and complicated skin and skin-structure infections, subject to the product’s approved labeling and susceptibility requirements [1].
When did Avelox lose exclusivity?
Avelox’s principal commercial exclusivity ended after expiration of the core moxifloxacin patent estate and associated regulatory exclusivities. The original branded product faced generic competition in the United States during the 2010s, including generic moxifloxacin tablets and injectable products.
The exact commercial erosion date differed by dosage form and manufacturer because generic approvals, launches, and supply arrangements occurred at different times. For the intravenous presentation, the key event was the approval of abbreviated new drug applications for moxifloxacin injection rather than continued reliance on the branded Avelox product.
Patent and exclusivity timeline
| Period |
Event |
Commercial effect |
| 1990s |
Bayer develops and patents moxifloxacin-related quinolone chemistry |
Creates originator protection |
| 1999-2000 |
Avelox receives U.S. approvals for oral and injectable use |
Branded market begins |
| 2000s |
Avelox expands across hospital and outpatient antibacterial markets |
Revenue growth and global adoption |
| Early 2010s |
Core patent and regulatory exclusivity protections approach expiration |
Generic entry becomes feasible |
| Mid-2010s |
Generic moxifloxacin products enter the U.S. market |
Rapid price and share erosion |
| 2020s |
Avelox operates as a mature or discontinued branded product in many markets |
Value shifts to generic supply |
Moxifloxacin’s core U.S. composition-of-matter protection was associated with Bayer patent filings covering quinolone derivatives. Public patent databases identify U.S. Patent No. 5,607,942 among the principal patents associated with the compound class. The patent’s ordinary term was not sufficient to preserve branded exclusivity after generic moxifloxacin entered the market.
What patents protect Avelox injection?
The original protection for Avelox centered on the active pharmaceutical ingredient and related quinolone chemistry, not on the plastic container alone. Potentially relevant categories included:
- Composition-of-matter patents covering moxifloxacin or related quinolone derivatives.
- Salt and crystalline-form patents.
- Pharmaceutical-composition claims involving moxifloxacin and infusion vehicles.
- Manufacturing and purification claims.
- Method-of-use claims for treating bacterial infections.
The 0.8% sodium chloride vehicle is commercially important but generally offers weaker standalone protection than a valid composition-of-matter patent. A flexible plastic container may involve container, compatibility, leachables, sterilization, or packaging claims, but those claims typically do not prevent a generic manufacturer from selling a substantially equivalent moxifloxacin infusion if the generic product satisfies FDA requirements.
Are formulation patents still commercially important?
Formulation patents can matter when they cover a specific concentration, stabilizer system, container material, sterilization process, or manufacturing method. Their practical value depends on claim scope and enforceability.
For Avelox injection, the principal commercial barrier was the injectable product itself: sterile manufacturing, validated aseptic or terminal-sterilization processes, container compatibility, particulate control, extractables and leachables testing, and reliable hospital distribution. These barriers are operational rather than brand-protective once generic approvals are available.
What is the Orange Book status of Avelox injection?
Avelox injection has been subject to FDA Orange Book and Drugs@FDA records associated with the innovator’s injectable new drug application. The commercial significance of the listing is limited after generic moxifloxacin injection approvals and the loss of effective branded exclusivity.
The Orange Book distinguishes between:
- Listed patents associated with an approved drug;
- Regulatory exclusivity periods;
- Therapeutic-equivalence evaluations for approved generic products;
- Current marketing status of the reference product.
A reference product can remain in regulatory records even when the brand has limited or no commercial presence. A discontinued designation does not by itself mean that the product was withdrawn for safety reasons. FDA records should be read separately from current market availability [2].
Which companies challenge or compete with Avelox?
The competitive field is dominated by generic injectable manufacturers and hospital-focused suppliers rather than by a single branded rival.
Primary competitors
Generic moxifloxacin injection may be supplied by companies such as:
- Sandoz;
- Hikma;
- Fresenius Kabi;
- Pfizer or legacy Hospira operations;
- Teva;
- Viatris or legacy Mylan operations;
- Other FDA-approved sterile-injectable manufacturers.
The precise active supplier set changes with shortages, manufacturing transfers, procurement awards, and product discontinuations. Hospital purchasing organizations often qualify several suppliers because injectable availability is more important than brand loyalty.
Therapeutic competitors
Avelox injection also competes clinically with other hospital antibiotics, including:
- Levofloxacin injection;
- Ciprofloxacin injection;
- Ceftriaxone;
- Cefepime;
- Piperacillin and tazobactam;
- Respiratory fluoroquinolone alternatives;
- Combination regimens selected by hospital antimicrobial-stewardship programs.
This competition limits the ability of any moxifloxacin supplier to raise prices materially, even when temporary shortages reduce the number of active suppliers.
What FDA regulatory issues affect Avelox demand?
Fluoroquinolone safety communications have reduced use in situations where alternative antibiotics are available. The FDA has warned about risks including tendinitis and tendon rupture, peripheral neuropathy, central nervous system effects, hypoglycemia, and potentially disabling adverse reactions [3].
In 2016, FDA strengthened warnings regarding disabling side effects and advised that systemic fluoroquinolones should generally be reserved for certain uncomplicated infections when alternative treatments are available [4]. In 2018, FDA issued a warning concerning the risk of aortic aneurysm and dissection in selected patients [5].
These warnings affect Avelox injection in two ways:
- They reduce elective or low-severity use.
- They preserve demand for hospital treatment where the drug’s spectrum, pharmacokinetics, allergy considerations, or clinical circumstances justify use.
The regulatory risk is therefore a demand constraint rather than a product-removal event. Moxifloxacin remains an FDA-approved antibacterial, but stewardship programs and safety warnings narrow its use.
How has the financial trajectory changed?
Avelox’s branded revenue trajectory followed the standard small-molecule lifecycle.
Phase 1: Branded expansion
Avelox generated value through patent-protected pricing, physician familiarity, broad antibacterial coverage, and use across oral and intravenous formulations. The injection added hospital utility and allowed treatment continuity when patients could not take oral medication.
The product was part of Bayer’s broader pharmaceutical portfolio. Bayer’s public reporting generally did not disclose revenue for the specific 400 mg/250 mL plastic-container presentation. Reported product sales were often grouped by brand, business segment, geography, or therapeutic area [6].
Phase 2: Generic entry
Generic entry reduced the addressable branded revenue base. Hospitals and group purchasing organizations typically evaluate injectable antibiotics through acquisition cost, supply reliability, therapeutic equivalence, and contract terms. Once equivalent generic products became available, Avelox lost pricing leverage.
The typical effects were:
- Lower average selling prices;
- Declining branded unit volume;
- Conversion from branded procurement to generic tenders;
- Greater sensitivity to shortages and manufacturing interruptions;
- Reduced promotional spending;
- Lower return on brand-specific commercial infrastructure.
Phase 3: Mature generic market
The current value pool is primarily the generic market for moxifloxacin injection. Revenue is distributed among manufacturers based on:
- Number of active suppliers;
- FDA approval status;
- Contract wins;
- Hospital formulary placement;
- Manufacturing capacity;
- Shortage conditions;
- Product discontinuations;
- Distribution relationships.
The product has limited opportunity for volume growth because fluoroquinolone stewardship constrains demand and hospitals have multiple substitutes. Financial upside is more likely to arise from supply consolidation or temporary shortages than from sustained brand expansion.
What generic entry risks exist for Avelox?
Generic entry risk is no longer prospective for the U.S. injectable product. It is an established commercial condition.
The principal risks are:
| Risk |
Effect on Avelox economics |
| Therapeutically equivalent generic injection |
Removes branded price premium |
| Multiple generic suppliers |
Increases price competition |
| Hospital purchasing contracts |
Concentrates negotiating power |
| Fluoroquinolone warnings |
Suppress clinical demand |
| Alternative antibiotics |
Reduce treatment share |
| Injectable manufacturing failures |
Create volatile supply conditions |
| Container and sterilization requirements |
Raise generic entry costs but do not preserve brand pricing |
| Brand discontinuation |
Reduces visibility and procurement preference |
For a new entrant, the principal barrier is not patent infringement exposure. It is the cost and complexity of FDA-compliant sterile manufacturing and the need to secure dependable commercial supply.
What is the biosimilar risk for Avelox?
Biosimilar risk is not relevant. Moxifloxacin is a chemically synthesized small molecule, not a biologic. Generic competition proceeds through the abbreviated new drug application pathway, with pharmaceutical equivalence and bioequivalence requirements rather than the biosimilar framework under the Public Health Service Act.
The relevant competitive risks are generic approval, therapeutic substitution, contract pricing, and manufacturing capacity.
What patent litigation and settlements affected Avelox?
The major commercial issue was the transition from branded to generic moxifloxacin. Publicly available product and FDA records do not establish an ongoing litigation barrier that would materially protect the Avelox 400 mg/250 mL infusion presentation today.
Paragraph IV litigation would have been relevant when generic applicants challenged listed patents before approval. After expiration or loss of practical relevance of the core patents, such litigation no longer provides a durable barrier to generic supply.
No current commercial premium should be assigned to the Avelox brand based on historical patent litigation or settlement activity. Any transaction valuation should instead examine the specific manufacturer’s approvals, product availability, contracts, and intellectual-property claims.
How does Avelox injection compare with levofloxacin injection?
| Category |
Avelox injection |
Levofloxacin injection |
| Active ingredient |
Moxifloxacin |
Levofloxacin |
| Class |
Fluoroquinolone |
Fluoroquinolone |
| Branded originator |
Bayer |
Johnson & Johnson / Ortho-McNeil originator history |
| Current market structure |
Predominantly generic |
Predominantly generic |
| Hospital use |
Selected respiratory and other susceptible infections |
Broad hospital and respiratory use |
| Patent value today |
Limited for the legacy brand |
Limited for the legacy brand |
| Main commercial driver |
Generic price and supply |
Generic price, supply, and broader utilization |
| Demand constraint |
Safety warnings and stewardship |
Safety warnings and stewardship |
Levofloxacin has historically had broader hospital utilization, while moxifloxacin retains a position in selected respiratory infections and other approved uses. Both products face the same structural risks from fluoroquinolone safety restrictions and generic price erosion.
What geographic markets remain commercially relevant?
The United States is a mature generic market. Europe and other developed markets also have extensive generic penetration, although brand retention, tender structures, reimbursement, and national authorization status differ.
Emerging markets may preserve branded or branded-generic demand, but pricing is generally lower and regulatory status varies. Commercial diligence should distinguish:
- Reference-brand sales;
- Authorized generics;
- Local branded generics;
- Hospital tender business;
- Private-sector pharmacy sales;
- Government procurement.
Avelox’s historical global presence does not imply that the same presentation remains marketed in every country.
Key Takeaways
- Avelox in Sodium Chloride 0.8% is a 400 mg/250 mL intravenous moxifloxacin product.
- Bayer originated the product, but the U.S. market is now primarily generic.
- The core patent estate no longer provides meaningful branded exclusivity.
- The formulation and plastic container create sterile-manufacturing requirements, not a durable premium moat.
- Biosimilar competition does not apply because moxifloxacin is a small molecule.
- Fluoroquinolone safety warnings and antimicrobial stewardship limit demand.
- Product-specific revenue for the plastic-container presentation was not separately disclosed in Bayer’s public reporting.
- Current commercial value depends on generic supply, hospital contracts, manufacturing reliability, and shortage conditions.
- A new entrant’s main risk is sterile-injectable execution, not current patent litigation.
FAQs
Is Avelox injection still sold in the United States?
The Avelox brand has limited commercial relevance in the United States, while generic moxifloxacin injection is the principal market supply. FDA product records and current distributor listings should be distinguished from active branded marketing.
What is the generic name for Avelox in Sodium Chloride 0.8%?
The generic name is moxifloxacin hydrochloride injection, commonly supplied as 400 mg in 250 mL of sodium chloride solution.
Is Avelox injection interchangeable with generic moxifloxacin?
Interchangeability depends on the FDA therapeutic-equivalence designation and the specific approved generic presentation. Hospital substitution also depends on institutional pharmacy policy and state law.
Does Avelox injection have pediatric exclusivity?
Avelox’s commercial exclusivity was primarily associated with the original patent and regulatory framework. Any pediatric-exclusivity period is historical and does not preserve current branded market protection.
What is the main investment risk in generic moxifloxacin injection?
The main risks are low pricing, concentrated hospital purchasing, limited clinical growth, sterile-manufacturing failures, supply shortages, and competition from alternative antibiotics.
References
- U.S. Food and Drug Administration. (2011). Avelox (moxifloxacin hydrochloride) injection prescribing information.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (2008). FDA strengthens boxed warning for fluoroquinolone antibacterial drugs due to risk of tendinitis and tendon rupture.
- U.S. Food and Drug Administration. (2016). FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects.
- U.S. Food and Drug Administration. (2018). FDA warns about increased risk of ruptures or tears in the aorta with fluoroquinolone antibiotics.
- Bayer AG. (2014). Annual report 2014.
- U.S. Patent and Trademark Office. (1997). U.S. Patent No. 5,607,942: Quinolone carboxylic acid derivatives.
